Home HOME Neoplasma 2015 Neoplasma Vol.62, No.1, p.152-158, 2014

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.62, No.1, p.152-158, 2014

Title: GROα expression and its prognostic implications in laryngeal squamous cell carcinoma
Author: L. HAN, W. LIU, Y. CHEN, H. WU, Y. ZHANG, B. JIANG

Abstract: The growth-regulated oncogene α (GROα) , which is also designated as CXC chemokine ligand 1 (CXCL1), was first identified as an autocrine growth factor in human malignant melanoma. It is involved in tumor development and invasion, and is highly expressed in various human cancers. However, little is known about the association between GROα expression and the clinical attributes of laryngeal squamous cell carcinoma (LSCC).
One-step quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and immunohistochemical staining of tissue microarrays were employed to evaluate the relationship between GROα expression and LSCC clinicopathological attributes.
GROα mRNA and protein expression levels were significantly greater in LSCC than in non-cancerous tumor-adjacent tissues. GROα protein expression in LSCC was also significantly associated with TNM stage, lymph node metastasis, and histopathological grade. Kaplan-Meier and Cox multi-factor analyses suggested that increased GROα expression and positive lymph node metastasis were significantly associated with the poor survival of LSCC patients.
These data indicate that GROα may be a novel prognostic marker of LSCC.

Keywords: GROα,LSCC,qPCR,immunohistochemistry, prognosis
Published online: 17-Oct-2014
Year: 2015, Volume: 62, Issue: 1 Page From: 152, Page To: 158

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.